Robert Rovner co-wrote this blog post with Sharon Karlsberg. This article originally appeared in the January 2019 issue of OBR Green.
The “first-mover advantage” is something we’ve come to expect in the commercial world. The first to innovate and come to market usually reaps the greatest rewards, right? Facebook, Uber and Google improved on technology brought to market by actual first-movers MySpace, Sidecar and AltaVista, but then transcended them by addressing their weaknesses.
Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.
At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.
Here are our top three takeaways from this year’s event: